{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.8","value":"636"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.1","value":"945"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"AUClast was defined as the area under the concentration-time curve up to the last measurable concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an \"extensive PK\" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the \"sparse PK\" sampling schedule.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PAS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose","title":"AUClast of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses","type":"SECONDARY","unitOfMeasure":"ng*hour/mL"}